Ocular inflammation in Cynomolgus Macaques following intravenous administration of a human monoclonal antibody

International Journal of Toxicology

Volumn 28, Issue 1, 2009, Pages 5-16

  Martin, Pauline L ^a   Miller, Paul E ^b   Mata, Marielena ^a   Christian, Brian J ^c  

^a CENTOCOR INC   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c 206 Carnegie Center   (United States)

Author keywords

Angiogenesis; Eye; Macaque; Monoclonal antibody; Ocular inflammation

Indexed keywords

BEVACIZUMAB; CNTO 95; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CNTO 95; TRASTUZUMAB; UNCLASSIFIED DRUG; ALPHA INTEGRIN; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTERIOR EYE CHAMBER; APPLICATION SITE DISCOMFORT; APPLICATION SITE INFLAMMATION; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SAFETY; EYE INFLAMMATION; EYE TOXICITY; FEMALE; FLUORESCENCE ANGIOGRAPHY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOLOCALIZATION; MACACA; MALE; NONHUMAN; REPEATED DRUG DOSE; RETREATMENT; ANIMAL; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; RETINA MACULA DEGENERATION; SUBRETINAL NEOVASCULARIZATION; TOXICITY TESTING; UVEITIS; VITREOUS BODY;

ANIMALIA; MACACA; RATTUS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTERIOR CHAMBER; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; FEMALE; INJECTIONS, INTRAVENOUS; INTEGRIN ALPHA CHAINS; MACACA FASCICULARIS; MACULAR DEGENERATION; MALE; TOXICITY TESTS; UVEITIS; VITREOUS BODY;

EID: 68049083569     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1177/1091581809333987     Document Type: Article

References (26)

1. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 2007;6:273-286.
2. Adamis AP, Aiello LP, D'Amato RA. Angiogenesis and ophthalmic disease. Angiogen. 1999;3:9-14.
3. Campochiaro PA, Soloway P, Ryan SJ, Miller JW. The pathogenesis of choroidal neovascularization in patients with age-related macular degeneration. Mol Vis. 1999;5: 34-38.
4. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
5. Harry LE, Paleolog EM. From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. Birth Def Res. 2003;69:363-374.
6. Caldwell RB, Bartoli M, Behzadian MA, et al. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Diabetes Metab Res Rev. 2003;19:442-455.
7. Eliceiri BP, Cheresh DA. The role of an integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J Clin Invest. 1999; 103: 227-1230.
8. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev. 2008;8: 604-617.
9. Trikha M, Zhou Z, Nemeth JA, et al. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo. Int J Cancer. 2004;110:326-335.
10. Chen Q, Manning SD, Millar H, et al. CNTO95, a fully human anti an integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells. Clin Exp Metastasis. 2007; 25:139-148.
11. Mullamitha SA, Ton SC, Parker GJM, et al. Phase I evaluation of a fully human anti-an-integrin monoclonal antibody (CNTO95) in patients with advanced solid tumors. Clin Cancer Res. 2007;13:2128-2135.
12. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today. 2007;12: 540-547.
13. Haller CA, Cosenza ME, Sullivan JT. Safety issues specific to clinical development of protein therapeutics. Clin Pharmacol Therapeut. 2008;84:624-627.
14. Martin PL, Jiao Q, Cornacoff J, et al. Absence of adverse effects in cynomolgus macaques treated with CNTO95, a fully human anti-an-integrin monoclonal antibody, despite widespread tissue binding. Clin Cancer Res. 2005;11:6959-6965.
15. Christian BJ, Nork T, Leedle RA, Miller JM, O'Neill CA. Characterization of a monkey model of laser-induced choroidal neovascularization. Toxicologist. 2003;77:311.
16. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
17. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol. 2005;123: 509-516.
18. Hogan MH, Kimura SJ, Thygeson P. Signs and symptoms of uveitis: I. Anterior uveitis. Am J Ophthalmol. 1959;47:155-170.
19. Mordenti J, Cuthbertson A, Ferrara N, et al. Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus macaques following intravitreal administration. Toxicol Pathol. 1999;27:536-544.
20. Hultsch E. Peripheral uveitis in the owl monkey. Mod Probl Ophthalmol. 1997;18:247-251.
21. Freddo TF, Bartels SP, Barsotti MF, Kamm RD. Morphologic correlations with fluorophotometric data from monkey eyes with anterior uveitis. Invest Ophthamol Vis Sci. 1992;33:1642-1649.
22. Rosenbaum JT, McDewitt HO, Guss RB, Egbert PR. Endotoxin-induced uveitis in rats as a model for human disease. Nature. 1980;286:611-613.
23. Davis HM, Prabhakar U, Jang H,et al. A rational approach for a phase I clinical study design to evaluate CNTO95, a novel, fully human anti-αv monoclonal antibody (MAb), in patients with solid tumors. J Clin Oncol. 2004;22:2609.
24. Hall WC, Price-Schiavi SA, Wicks J, Rojka JL. Tissue cross-reactivity studies for monoclonal antibodies: predictive value and use for the selection of relevant animal species in toxicity testing. In: Cavagnaro JA, ed. Preclinical Safety Evaluation of Biopharmaceuticals. Hoboken, NJ: John Wiley; 2008:207-240.
25. Rojka JL, Price-Schiavi SA. Physiologic IgG biodistribution, transport, and clearance: implications for monoclonal antibody products. In: Cavagnaro JA, ed. Preclinical Safety Evaluation of Biopharmaceuticals. Hoboken, NJ: John Wiley; 2008:241-276.
26. O'Day S, Pavlick A, Loquai C, et al. Phase 2 study of the safety and efficacy of the human monoclonal antibody CNTO 95 alone and in combination with dacarbazine in patients with stage IV metastatic melanoma: interim results [abstract]. Perspect Melanoma. 2008;12:P-064.